Sunday, 9 November 2014

Lymphopenia after Gilenya

Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC.Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology. 2014 Oct 31. pii: 10.1212/WNL.0000000000001049. [Epub ahead of print]

OBJECTIVE:To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remitting multiple sclerosis (RRMS).
METHODS:Data were obtained from a German multicenter, single-arm, open-label study of patients with RRMS treated with fingolimod, and findings were validated in an independent Swedish national pharmacovigilance study.
RESULTS:Four hundred eighteen patients with RRMS from Germany and 438 patients from Sweden were included. A nadir ≤0.2 × billion lymphocytes/Litre was reached in 15% (95% confidence interval [CI] 12%-17%) of all 856 patients. Patients with lower starting lymphocyte counts (below 1.6 billion cells/litre) and patients with BMI lower than 18.5 kg/m2 (women only) were at higher risk of developing lymphopenia with values ≤0.2 × 109/L in the combined analysis, increasing the risk in these subgroups to 26% (95% CI 20%-31%) or 46% (95% CI 23%-71%), respectively. In the German cohort, infection rates were similar in patients who developed severe lymphopenia and those who did not.
CONCLUSIONS: Our findings suggest that patients with low baseline lymphocyte counts and underweight women in which fingolimod treatment will be initiated should possibly be monitored more closely.


Lymphopaenia has become a hot topic with the report of PML in someone who was lymphopenic after taking Tecfidera. Lymphopaenia in the blood is thought to be the functional mechanism of action of many drugs as it is stopping the availability of white cells getting into the brain. It happens with Lemtrada and it happens with Gilenya too. This report indicates that low starting white cell counts and low body mass index (maybe you get relatively more drug per killogram from a standard sized pill) were a risk factor for lymphopaenia. Have there been cases of PML in people taking Gilenya? Yes there have been, but many have been associated from the switch over from natiluzimab and the infection may have been sub clinical during Tysabri infusions. 

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.